Brokerages issue new calls and target revisions for Delhivery, NSE, Reliance, Bank of Baroda and others

摘要

Major brokerages released fresh recommendations, earnings updates and price target adjustments for a range of Indian stocks ahead of today’s trading session.

Brokerages highlighted investment opportunities across logistics, pharmaceuticals, exchanges, banking, chemicals, oil and gas, and electronics sectors, issuing new calls and revising targets for companies such as Delhivery Ltd, National Stock Exchange (NSE), Reliance Industries Ltd, Bank of Baroda, Muthoot Finance, Sun Pharmaceutical Industries, Navin Fluorine, GAIL (India) Ltd, Bharat Electronics Ltd, PB Fintech Ltd and several others.

JPMorgan maintained an Overweight rating on Delhivery, keeping its target price at Rs 590, and raised its FY27 earnings per share estimate by 10.9% after reporting a 20% YoY revenue increase in Q2. Jefferies cut its target price for Delhivery to Rs 470, citing margin expansion from price hikes and operating leverage, while Kotak retained a Buy rating with a target of Rs 550. Citi also kept a Buy stance, adjusting the target to Rs 545 and noting stronger yields despite softer volumes.

JPMorgan initiated coverage of NSE with an Overweight rating and a target price of Rs 2,130, projecting an improvement in EBITDA margins and a 14% adjusted profit CAGR through FY29. For Bank of Baroda, JPMorgan maintained Overweight, lowering the target to Rs 310, and highlighted a 9% YoY rise in net interest income and a 36% increase in core profit. HSBC upgraded the bank to Buy, raising its target to Rs 284 and emphasizing stronger fee income and lower credit costs.

Reliance Industries retained an Overweight rating from JPMorgan, with the target price lifted to Rs 1,675 after a 23% YoY rise in consolidated EBITDA and a 41% jump in profit. Jefferies kept a Buy rating, setting a target of Rs 1,710, while noting a decline in retail EBITDA.

Muthoot Finance remained a Hold for Jefferies, with the target cut to Rs 2,700 after a 27% YoY profit increase and a 42% rise in assets under management. Navin Fluorine received a Buy rating from Jefferies with a target of Rs 10,540 following a 57% YoY revenue growth, while Kotak maintained a Sell rating, citing expensive valuations.

GAIL held a Buy rating from Citi with a target of Rs 200, after EBITDA beat estimates driven by strong gas trading and transmission performance. Jefferies kept a Hold rating, setting a target of Rs 185 and noting a doubling of Q2 EBITDA.

Sun Pharmaceutical Industries stayed a Buy for HSBC with a target of Rs 2,050, after reporting a 12% YoY revenue rise and noting US FDA approval for Ilumya in psoriatic arthritis. BofA maintained an Underperform rating, lowering its target to Rs 1,850.

Bharat Electronics retained a Buy rating from HSBC with a target of Rs 525, reporting a 26.5% YoY revenue increase. PB Fintech kept a Buy rating from Jefferies with a target of Rs 1,540, despite a miss on adjusted EBITDA due to higher expenses.

Varun Beverages maintained Buy ratings from HSBC and Goldman Sachs, with targets of Rs 540 and Rs 520 respectively, after reporting strong volume growth and revenue gains, though margins were pressured by packaging inflation.

Other companies receiving coverage included Welspun Living, Welspun Corp, Dixon Technologies, Zee Entertainment, Max Healthcare, Alivus Life Sciences and several real estate and hospitality firms, each with updated earnings estimates and target price adjustments based on recent quarterly performance.

The brokerage notes collectively underscore a mix of earnings beats, margin expansions, and sector-specific risks such as Meesho’s insourcing for Delhivery, regulatory changes for NSE, and input-cost inflation for consumer-goods makers.

继续阅读——免费

创建免费账户以关注新闻。无需银行卡。